US 12,239,708 B2
Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
Karim Amighi, Brussels (BE); Nathalie Wauthoz, Brussels (BE); and Rémi Rosière, Brussels (BE)
Assigned to UNIVERSITÉ LIBRE DE BRUXELLES, Brussels (BE)
Appl. No. 17/295,610
Filed by UNIVERSITÉ LIBRE DE BRUXELLES, Brussels (BE)
PCT Filed Dec. 27, 2019, PCT No. PCT/EP2019/087122
§ 371(c)(1), (2) Date May 20, 2021,
PCT Pub. No. WO2020/136276, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 18248302 (EP), filed on Dec. 28, 2018.
Prior Publication US 2022/0016247 A1, Jan. 20, 2022
Int. Cl. A61K 47/14 (2017.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 47/14 (2013.01) [A61K 9/0075 (2013.01); A61K 45/06 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A dry powder inhalation formulation comprising at least one active pharmaceutical ingredient (API) and a lipid matrix comprising a mixture of monohydroxystearin, dihydroxystearin, and trihydroxystearin, wherein said dry powder inhalation formulation has a weight ratio between said at least one API and said lipid matrix: between 0.1/99.9 and 88/12.